Journal article
PD185 Is The Incorporation Of Medications For Ultrarare Diseases In Brazil Predominantly Driven By Costs? A Shift In Paradigm
Abstract
Incorporating technologies for ultrarare diseases (URD) poses challenges for global health technology assessment (HTA) agencies. Difficulties include defining an analytical framework and establishing differentiated cost-effectiveness thresholds. The rise of technological innovations intensifies demands from healthcare professionals, media, and the general population, placing pressure on healthcare systems in developing countries.
Authors
da Silva Pereira Curado D; Machado-Rugolo J; Komoda DS; de Sordi MADP; de Almeida JTC; Fonseca A; Lima SM; Weber SAT; de Andrade LGM; Tarride J-E
Journal
International Journal of Technology Assessment in Health Care, Vol. 40, No. S1, pp. s162–s163
Publisher
Cambridge University Press (CUP)
Publication Date
12 2024
DOI
10.1017/s0266462324004070
ISSN
0266-4623